Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma.
Transl Oncol., Aug;5(4):247-51 (2012)
Nonrecommended breast and colorectal cancer screening for young women: a vignette-based survey.
Am J Prev Med., Sep;43(3):231-9 (2012)
Ovarian cancer: screening and early detection.
Obstet. Gynecol. Clin. North Am., Jun;39(2):183-94 (2012)
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
J. Clin. Oncol., Jun;30(17):2039-45 (2012)
Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Int. J. Gynecol. Cancer., May;22(4):546-52 (2012)
Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations?
Ann. Intern. Med., Feb;156(3):182-94 (2012)
Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability.
Gynecol. Oncol., Feb;124(2):230-5 (2012)
Involvement in decision-making about treatment and ovarian cancer survivor quality of life.
Gynecol. Oncol., Mar;124(3):465-70 (2012)
Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.
Gynecol. Oncol., Dec;123(3):461-6 (2011)
Involvement of gynecologic oncologists in the treatment of patients with a suspicious ovarian mass.
Obstet Gynecol., Oct;118(4):854-62 (2011)
Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly.
Obstet Gynecol., Sep;118(3):537-47 (2011)
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
Cancer., Aug;117(16):3731-40 (2011)
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.
Cancer., Dec;117(23):5334-43 (2011)
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.
Am. J. Obstet. Gynecol., Jun;204(6):466-78 (2011)
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Gynecol. Oncol., Jul;122(1):100-6 (2011)
Patterns of spread and recurrence of sex cord-stromal tumors of the ovary.
Gynecol. Oncol., Aug;122(2):242-5 (2011)
How are symptoms of ovarian cancer managed? A study of primary care physicians.
Cancer., Oct;117(19):4414-23 (2011)
Pelvic exenteration in the age of modern chemoradiation.
Gynecol. Oncol., Apr;121(1):131-4 (2011)
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
Neoplasia., Dec;12(12):993-1002 (2010)
FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence.
Gynecol. Oncol., Feb;120(2):296-9 (2011)
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.
Cancer., Nov;116(22):5261-71 (2010)
Training and assessment in gynaecologic surgery: the role of simulation.
Best Pract Res Clin Obstet Gynaecol., Dec;24(6):759-66 (2010)
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.
Genes Chromosomes Cancer., Jul;49(7):577-84 (2010)
The abandoned radical hysterectomy for cervical cancer: clinical predictors and outcomes.
Obstet Gynecol Int., 2010:743794 (2010)
Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction.
Gynecol. Oncol., Jul;118(1):43-6 (2010)
Identification of ovarian cancer symptoms in health insurance claims data.
J Womens Health (Larchmt)., Mar;19(3):381-9 (2010)
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.
Gynecol. Oncol., Mar;116(3):378-83 (2010)
Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gynecol. Oncol., Mar;116(3):340-4 (2010)
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Mol. Cancer., 8:48 (2009)
Surgical education for gynecologic oncologists.
Gynecol. Oncol., Aug;114(2 Suppl):S45-6 (2009)
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.
Gynecol. Oncol., Aug;114(2):225-30 (2009)
Factors affecting risk of mortality in women with vaginal cancer.
Obstet Gynecol., May;113(5):1038-45 (2009)
Training the next generation of minimally invasive surgeons.
J Minim Invasive Gynecol., 16(2):136-41 (2009 Mar-Apr)
Changing the paradigm in surgical education.
Obstet Gynecol., Aug;112(2 Pt 1):328-32 (2008)
Combining a symptoms index with CA 125 to improve detection of ovarian cancer.
Cancer., Aug;113(3):484-9 (2008)
Quality measures in gynecologic cancers: what and when?
Gynecol. Oncol., Jul;110(1):3-4 (2008)
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Gynecol. Oncol., Aug;110(2):146-51 (2008)
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.
Cancer Genet. Cytogenet., May;183(1):41-8 (2008)
Surgical education: what role should gynecologic oncologists play?
Gynecol. Oncol., May;109(2):164-5 (2008)
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
Gynecol. Oncol., May;109(2):215-9 (2008)
An evaluation of cervical cancer in women age sixty and over.
Gynecol. Oncol., Apr;109(1):53-8 (2008)
Comparison of objective, structured assessment of technical skills with a virtual reality hysteroscopy trainer and standard latex hysteroscopy model.
J Reprod Med., May;52(5):407-12 (2007)
Predictors of comprehensive surgical treatment in patients with ovarian cancer.
Cancer., May;109(10):2031-42 (2007)
Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Hum. Pathol., Apr;38(4):607-13 (2007)
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
Genes Chromosomes Cancer., Mar;46(3):239-47 (2007)
Development of an ovarian cancer symptom index: possibilities for earlier detection.
Cancer., Jan;109(2):221-7 (2007)
Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma.
Gynecol. Oncol., Dec;103(3):793-6 (2006)
Ovarian cancer: patterns of surgical care across the United States.
Gynecol. Oncol., Nov;103(2):383-90 (2006)
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Am. J. Obstet. Gynecol., Jun;194(6):1702-9 (2006)
Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium.
Gynecol. Oncol., Jun;101(3):429-35 (2006)
A six-year study of surgical teaching and skills evaluation for obstetric/gynecologic residents in porcine and inanimate surgical models.
Am. J. Obstet. Gynecol., Dec;193(6):2056-61 (2005)
A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS).
Am. J. Obstet. Gynecol., Nov;193(5):1856-65 (2005)
Self-assessment of resident surgical skills: is it feasible?
Am. J. Obstet. Gynecol., Nov;193(5):1817-22 (2005)
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer.
Am. J. Obstet. Gynecol., Sep;193(3 Pt 1):662-7 (2005)
Uterine papillary serous carcinoma: what have we learned over the past quarter century?
Gynecol. Oncol., Sep;98(3):341-3 (2005)
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.
JAMA., Jun;291(22):2705-12 (2004)
Evaluation of postoperative fever: usefulness and cost-effectiveness of routine workup.
Am. J. Obstet. Gynecol., Jun;188(6):1642-7 (2003)
Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications.
Cancer Causes Control., Feb;13(1):35-45 (2002)
Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Gynecol. Oncol., Sep;70(3):378-85 (1998)
Adenocarcinoma of the uterine cervix metastatic to lymph nodes.
Am. J. Obstet. Gynecol., Jun;178(6):1131-7 (1998)
Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients.
Gynecol. Oncol., Apr;69(1):69-73 (1998)
Mesothelial pelvic lymph node inclusions mimicking metastatic thyroid carcinoma.
Gynecol. Oncol., Feb;68(2):210-3 (1998)
Comparison of 1997 Medicare relative value units for gender-specific procedures: is Adam still worth more than Eve?
Gynecol. Oncol., Aug;66(2):313-9 (1997)
Intraperitoneal spread of cervical carcinoma after laparoscopic lymphadenectomy.
Obstet Gynecol., May;89(5 Pt 2):864 (1997)
Is Adam worth more than Eve? The financial impact of gender bias in the federal reimbursement of gynecological procedures.
Gynecol. Oncol., Mar;64(3):372-7 (1997)
Expanded pelvic radiotherapy fields for treatment of local-regionally advanced carcinoma of the cervix: outcome and complications.
Am. J. Obstet. Gynecol., Apr;174(4):1141-9; discussion 1149-50 (1996)
Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
Eur. J. Gynaecol. Oncol., 17(6):487-92 (1996)
The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma.
Gynecol. Oncol., Jan;60(1):81-8 (1996)
Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases.
Gynecol. Oncol., Dec;59(3):384-9 (1995)
Malignant mixed mÃ¼llerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy.
Cancer., Oct;76(7):1209-13 (1995)
Clinicopathologic variables, operative characteristics, and DNA ploidy in predicting outcome in ovarian epithelial carcinoma.
Obstet Gynecol., Sep;86(3):379-85 (1995)
Uterine papillary serous carcinoma: patterns of metastatic spread.
Gynecol. Oncol., Sep;54(3):264-8 (1994)
Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model.
Br. J. Cancer., Sep;70(3):474-80 (1994)
Human papillomavirus typing in patients with Papanicolaou smears showing squamous atypia.
Gynecol. Oncol., Mar;48(3):384-8 (1993)
Effects of photodynamic therapy with topical application of 5-aminolevulinic acid on normal skin of hairless guinea pigs.
J. Photochem. Photobiol. B, Biol., Aug;15(3):239-51 (1992)
Post-hysterectomy carcinoma of the fallopian tube mimicking a vesicovaginal fistula.
Obstet Gynecol., May;79(5 ( Pt 2)):853-6 (1992)
Endocervical glandular atypia in Papanicolaou smears.
Obstet Gynecol., Jan;79(1):101-4 (1992)
Photoimmunotherapy of human ovarian carcinoma cells ex vivo.
Cancer Res., Sep;51(18):4762-7 (1991)
Tuberculous endometritis presenting as postmenopausal bleeding. A case report.
J Reprod Med., Aug;36(8):616-8 (1991)
Combination chemotherapy in advanced adenocarcinoma of the fallopian tube.
Gynecol. Oncol., Mar;40(3):268-73 (1991)
Assessment of depth of myometrial invasion in endometrial adenocarcinoma.
Gynecol. Oncol., Jul;38(1):46-8 (1990)
Gunshot wounds to the gravid uterus. A case report.
J Reprod Med., Apr;35(4):436-8 (1990)
Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin and cisplatin regimen.
Eur. J. Gynaecol. Oncol., 11(4):263-8 (1990)